血糖达标时间作为一项研究结果指标。
Time in Range as a Research Outcome Measure.
作者信息
Timmons Joseph G, Boyle James G, Petrie John R
机构信息
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, U.K.
Department of Endocrinology and Diabetes, Glasgow Royal Infirmary, Glasgow, Scotland, U.K.
出版信息
Diabetes Spectr. 2021 May;34(2):133-138. doi: 10.2337/ds20-0097. Epub 2021 May 25.
Abstract
Time in range (TIR) is gaining ground as an outcome measure in type 1 diabetes trials. However, inclusion of TIR raises several issues for trial design. In this article, the authors begin by defining TIR and describing the current international consensus around TIR targets. They then expand on evidence for the validity of TIR as a primary clinical trial outcome before concluding with some practical, ethical, and logistical implications.
摘要
血糖达标时间（TIR）作为1型糖尿病试验的一项结局指标正逐渐受到重视。然而，将TIR纳入考量给试验设计带来了几个问题。在本文中，作者首先对TIR进行了定义，并描述了当前围绕TIR目标的国际共识。然后，他们详细阐述了TIR作为主要临床试验结局有效性的证据，最后得出了一些实际、伦理和后勤方面的影响。
相似文献
1
Time in Range as a Research Outcome Measure.血糖达标时间作为一项研究结果指标。
Diabetes Spectr. 2021 May;34(2):133-138. doi: 10.2337/ds20-0097. Epub 2021 May 25.
2
The Optimal "Time in Range" and "Time below Range" are Difficult to Coordinate in Patients with Type 1 Diabetes.对于 1 型糖尿病患者来说，“目标范围内时间”和“血糖低于目标范围时间”很难兼顾。
Tohoku J Exp Med. 2021 Nov;255(3):221-227. doi: 10.1620/tjem.255.221.
3
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
Clinical Application of Time in Range and Other Metrics.血糖在目标范围内时间及其他指标的临床应用
Diabetes Spectr. 2021 May;34(2):109-118. doi: 10.2337/ds20-0093. Epub 2021 May 25.
5
Association of Time in Range levels with Lower Extremity Arterial Disease in patients with type 2 diabetes.2型糖尿病患者血糖达标时间与下肢动脉疾病的关联
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2081-2085. doi: 10.1016/j.dsx.2020.09.028. Epub 2020 Sep 28.
6
Performance of Italian Consensus for the Classification and Reporting of Thyroid Cytology (ICCRTC) in discriminating indeterminate lesions at low and high risk of malignancy. A systematic review and meta-analysis.意大利甲状腺细胞病理学分类和报告共识（ICCRTC）在鉴别低危和高危恶性肿瘤不确定病变中的性能。系统评价和荟萃分析。
Endocrine. 2018 Apr;60(1):31-35. doi: 10.1007/s12020-017-1382-6. Epub 2017 Aug 7.
7
Association between time in range and cancer mortality among patients with type 2 diabetes: a prospective cohort study.2 型糖尿病患者的血糖达标时间与癌症死亡率之间的关联：一项前瞻性队列研究。
Chin Med J (Engl). 2021 Sep 15;135(3):288-294. doi: 10.1097/CM9.0000000000001740.
8
Time in blood glucose range 70 to 140 mg/dl >80% is strongly associated with increased survival in non-diabetic critically ill adults.血糖水平在70至140毫克/分升范围内的时间占比>80%与非糖尿病重症成年患者生存率提高密切相关。
Crit Care. 2015 Apr 20;19(1):179. doi: 10.1186/s13054-015-0908-7.
9
Continuous glucose monitoring defined time-in-range is associated with sudomotor dysfunction in type 2 diabetes.连续血糖监测定义的血糖在目标范围内的时间与2型糖尿病患者的汗腺功能障碍相关。
World J Diabetes. 2020 Nov 15;11(11):489-500. doi: 10.4239/wjd.v11.i11.489.
10
Socioeconomic status and time in glucose target range in people with type 2 diabetes: a baseline analysis of the GP-OSMOTIC study.2型糖尿病患者的社会经济地位与血糖目标范围内的时间：GP-OSMOTIC研究的基线分析
BMC Endocr Disord. 2018 Jul 21;18(1):47. doi: 10.1186/s12902-018-0279-6.
引用本文的文献
1
Glucometrics and Patient-Reported Outcomes in Individuals With Type 1 Diabetes Mellitus: Insights From the Correlation of Time in Range (CorrelaTIR) Study in Real-World Settings.1型糖尿病患者的血糖监测指标与患者报告结局：来自现实环境中血糖达标时间相关性（CorrelaTIR）研究的见解
Cureus. 2025 Feb 17;17(2):e79134. doi: 10.7759/cureus.79134. eCollection 2025 Feb.
2
Long-term health benefit and economic return of time in range (TIR) improvement in individuals with type 2 diabetes.2型糖尿病患者改善血糖在目标范围内时间（TIR）的长期健康益处和经济回报
Diabetes Obes Metab. 2025 Mar;27(3):1564-1571. doi: 10.1111/dom.16168. Epub 2025 Jan 8.
3
Quality of Life and Its Association With Time in Range Among People With Type 2 Diabetes Mellitus Following Different Dietary Interventions: A Crossover Clinical Trial.2型糖尿病患者在不同饮食干预后生活质量及其与血糖达标时间的关联：一项交叉临床试验
Cureus. 2024 Apr 4;16(4):e57624. doi: 10.7759/cureus.57624. eCollection 2024 Apr.
4
Investigating the value of glucodensity analysis of continuous glucose monitoring data in type 1 diabetes: an exploratory analysis.探究1型糖尿病连续血糖监测数据的葡萄糖密度分析价值：一项探索性分析。
Front Clin Diabetes Healthc. 2023 Sep 11;4:1244613. doi: 10.3389/fcdhc.2023.1244613. eCollection 2023.
5
Time in Range Estimation in Patients with Type 2 Diabetes is Improved by Incorporating Fasting and Postprandial Glucose Levels.纳入空腹和餐后血糖水平可改善2型糖尿病患者的血糖达标时间估算。
Diabetes Ther. 2023 Aug;14(8):1373-1386. doi: 10.1007/s13300-023-01432-2. Epub 2023 Jun 16.
本文引用的文献
1
Glycemic Status Assessment by the Latest Glucose Monitoring Technologies.最新血糖监测技术的血糖状态评估。
Int J Mol Sci. 2020 Nov 3;21(21):8243. doi: 10.3390/ijms21218243.
2
Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study.时间在范围内与 2 型糖尿病患者的全因和心血管死亡率的关系：一项前瞻性队列研究。
Diabetes Care. 2021 Feb;44(2):549-555. doi: 10.2337/dc20-1862. Epub 2020 Oct 23.
3
Practical estimation of cloud storage costs for clinical genomic data.临床基因组数据云存储成本的实际估算
Pract Lab Med. 2020 May 15;21:e00168. doi: 10.1016/j.plabm.2020.e00168. eCollection 2020 Aug.
4
InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design.InRange：使用连续血糖监测的1型糖尿病患者中第二代基础胰岛素类似物甘精胰岛素300 U/mL与德谷胰岛素100 U/mL的比较——研究设计
Diabetes Ther. 2020 Apr;11(4):1017-1027. doi: 10.1007/s13300-020-00781-6. Epub 2020 Feb 25.
5
Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes.在 1 型糖尿病成人中，C 肽保存与较少的低血糖事件和闪光葡萄糖监测的葡萄糖变异性降低相关。
Diabetologia. 2020 May;63(5):906-914. doi: 10.1007/s00125-020-05099-3. Epub 2020 Feb 7.
6
7. Diabetes Technology: .7. 糖尿病技术：。
Diabetes Care. 2020 Jan;43(Suppl 1):S77-S88. doi: 10.2337/dc20-S007.
7
6. Glycemic Targets: .6. 血糖目标： 。
Diabetes Care. 2020 Jan;43(Suppl 1):S66-S76. doi: 10.2337/dc20-S006.
8
Budgeting of non-commercial clinical trials: development of a budget tool by a public funding agency.非商业性临床试验的预算编制：公共资助机构开发预算工具
Trials. 2019 Dec 11;20(1):714. doi: 10.1186/s13063-019-3900-8.
9
Positioning time in range in diabetes management.糖尿病管理中的定位时间在范围内。
Diabetologia. 2020 Feb;63(2):242-252. doi: 10.1007/s00125-019-05027-0. Epub 2019 Nov 7.
10
Time in Range Is Associated with Carotid Intima-Media Thickness in Type 2 Diabetes.达标时间与 2 型糖尿病患者颈动脉内中膜厚度相关。
Diabetes Technol Ther. 2020 Feb;22(2):72-78. doi: 10.1089/dia.2019.0251. Epub 2019 Oct 11.
Zotero 插件